<DOC>
	<DOC>NCT02322216</DOC>
	<brief_summary>The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.</brief_summary>
	<brief_title>Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Chinese ethnicity; History of allergic conjunctivitis within the last 2 years; Positive skin prick test or skin intradermal test documented by a lab report within 24 months of, or at the baseline visit; Clinical diagnosis of allergic conjunctivitis with specific signs and symptoms; Understand and sign an informed consent form; Willing and able to make required study visits and follow study instructions, and comply with dosing study medication as instructed; Other protocolspecified inclusion criteria may apply. Contraindications or hypersensitivity to study medications or their components; Bestcorrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to approximately 0.60 logMAR, 20/80 Snellen, or 0.25 decimal) in either eye; Any ocular condition that could affect the study outcomes; Presumed or actual ocular infection or history of ocular herpes in either eye; Known history of retinal detachment, diabetic retinopathy, or any progressive retinal disease; Willing and able to avoid the use of any other topical ocular medication(s) (including artificial tear products); Any significant illness that could be expected to interfere with the study, particularly any autoimmune disease; Intraocular surgery in either eye within 6 months, or ocular laser surgery in either eye within 3 months, or anticipation of ocular surgery during the study; ocular trauma in either eye within 3 months of baseline visit; Clinically relevant recent (within 6 months of baseline visit) history of or current severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, autoimmune disease and other relevant systemic diseases that would preclude the safe administration of a topical antihistamine/mast cell stabilizer in the opinion of the Investigator; Use of systemic medication(s) on a chronic dosing regimen for less than 1 month or have changed dosage within the month prior to baseline visit; Use of any disallowed medication (topical, topical ophthalmic, systemic and/or injectable) during the period indicated prior to baseline visit. These medications are also not allowed during the study. Disallowed medications include all antiallergy therapies including those contained in prescription or overthecounter sleeping aids; Use of cold compresses on the eyes during the course of the study; Cannot be dosed in both eyes; Cannot avoid contact lens wear during the course of the study; Therapy with another investigational agent within 30 days of baseline visit, or during the study; Women of childbearing potential who are pregnant, intend to become pregnant during the study period, breastfeeding, or not using adequate birth control methods; Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Allergies</keyword>
	<keyword>Ocular</keyword>
</DOC>